TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06629272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D-THIO (Deprescribing Thyroid Hormone In Older Adults)
Description: D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER (Eliminating Medications through Patient Ownership of End Results) brochures to their patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
Study: NCT04446039

Intervention type: DRUG
Intervention: Escitalopram
Description: Treatment for depression

Intervention type: DRUG
Intervention: Paroxetine
Description: Treatment for depression

Intervention type: DRUG
Intervention: Fluoxetine
Description: Treatment for depression

Intervention type: DRUG
Intervention: Mirtazapine
Description: Treatment for depression

Intervention type: DRUG
Intervention: Duloxetine
Description: Treatment for depression

Intervention type: DRUG
Intervention: Sertraline
Description: Treatment for depression

Intervention type: DRUG
Intervention: Venlafaxine
Description: Treatment for depression

Intervention type: DRUG
Intervention: Tianeptine
Description: Treatment for depression

Intervention type: DRUG
Intervention: Vortioxetine
Description: Treatment for depression
Study: NCT05850650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of a collagen sponge after surgical extraction of impacted 3rd molar
Description: Application of a collagen sponge after surgical extraction of impacted 3rd molar
Study: NCT04446039

Intervention type: DRUG
Intervention: Desvenlafaxine
Description: Treatment for depression

Intervention type: DRUG
Intervention: Bupropion
Description: Treatment for depression
Study: NCT06699849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL889
Description: CSL889 is a solution for infusion to be administered by the IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL889
Description: CSL889 is a solution for infusion to be administered by the IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL889
Description: CSL889 is a solution for infusion to be administered by the IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL889
Description: CSL889 is a solution for infusion to be administered by the IV route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume and regimen matched to CSL899 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume and regimen matched to CSL899 will be administered.
Study: NCT06724952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX S.C or IM and Silymarin 140 mg tab
Description: IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX S.C or IM
Description: IM or SC Methotrexate plus placebo tablet once daily for 3 months.
Study: NCT06722378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to medical notes
Description: Inpatient notes shared in real-time on a hospital-owned bedside tablet linked to their child's records.
Study: NCT06723002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atherolive 500mg/day
Description: Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atherolive 1000/day
Description: Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placbo_Atherolive
Description: Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).
Study: NCT06724705

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose
Description: Participants receive lactose to determine whether it changes gut microbial hydrogen production

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: Participants will consume sucrose which they will consume as a placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear smart underwear
Description: Participants will wear the smart underwear device to measure the microbiome activity index

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wear smart underwear
Description: Participants will wear the smart underwear device to measure the microbiome activity index
Study: NCT06722287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Mental Health Mobile Application Intervention
Description: The mobile application includes self-care tools, caregiving management tools, and online support groups
Study: NCT06724172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management
Description: We will universally offer social needs supports (grocery, physical activity, transportation support) widely in use in clinical settings. Patients may elect to receive all, some, or none of the supports. The patient-directed, structured self-management intervention will be provided through mobile health technology (mHealth) and/or mailings, according to patient preference. Participants will receive health information to support health education and behavior change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Based
Description: As is currently in use broadly by community health workers, participants will complete a detailed social needs assessment and active assistance with referrals to evidence-based home visiting programs; maternal child health services to promote social support and resource access; and services to improve social determinants of health including active enrollment assistance for WIC, SNAP, healthcare and insurance, legal support, housing, job training, mental health and others. Community health workers will deliver group and individual physical activity support and assistance with behavioral goal setting.
Study: NCT06724926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Azeliragon is orally administered. Patients start Azeliragon 7 days before CSI and take their last dose 7 days post-CSI.~The first 6 patients will start at Dose Level 1 \[DL1\] (Loading dose for 7 days: 30 mg twice daily; Concurrent/adjuvant dose: 20 mg once daily).~If 1 or fewer of 6 patients develop dose-limiting toxicity (DLT) then the recommended dose will be DL1. If at least 2 of 6 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -1 \[DL-1\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 10mg once daily).~If 1 or fewer out of 6 patients at DL-1 develop DLT, then the recommended dose will be DL-1. If at least 2 of 6 at DL-1 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -2 \[DL-2\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 5mg once daily).~At the recommended dose, an additional 14 patients will be enrolled for the Dose Expansion portion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSI
Description: Patients will receive CSI.
Study: NCT06724809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.
Study: NCT06722339

Intervention type: DEVICE
Group type: OTHER
Intervention: low intensity transcranial focused ultrasound stimulation (TUS)
Description: Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects.

Intervention type: DEVICE
Group type: OTHER
Intervention: low intensity transcranial focused ultrasound stimulation (TUS)
Description: Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects.
Study: NCT06724692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-processed breakfast
Description: With this intervention, participants will consume ultra-processed foods

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-processed breakfast
Description: With this intervention, participants will consume low-processed foods
Study: NCT06723119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol (VRES) 500 mg oral once daily.
Description: Resveratrol supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500 mg oral once daily.
Description: Placebo will be supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
Study: NCT06722300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic teeth cleaning plus Tinidazole microneedle patches applying
Description: After gargling with compound chlorhexidine rinse or 3% hydrogen peroxide rinse for 1 minute, ultrasonic teeth cleaning was performed. After teeth cleaning, the wound was rinsed with 3% hydrogen peroxide and bleeding was stopped. After ultrasonic teeth cleaning, two metronidazole oral composite microneedle patches were immediately applied to the upper and lower gums near the inner side of the first molar, especially where the teeth were lost or damaged. The mouth was kept closed for 15 minutes. After the microneedles were fully degraded, the patient could leave the clinic.
Study: NCT04742114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use the face mask with Expiratory Positive Airway Pressure(EPAP).
Description: The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: use the face mask without Expiratory Positive Airway Pressure(EPAP).
Description: The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
Study: NCT04601805

Intervention type: DEVICE
Intervention: Observation
Description: We will record the vascular changes that follow the inflammatory bowel diseases

Intervention type: DEVICE
Intervention: Observation
Description: We will record the vascular changes that follow the inflammatory bowel diseases
Study: NCT05850650

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No collagen sponge application after surgical extraction of impacted 3rd molar
Description: No collagen sponge application after surgical extraction of impacted 3rd molar
Study: NCT06424886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Landing error scoring system (LESS)
Description: Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Landing error scoring system (LESS)
Description: Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Landing error scoring system (LESS)
Description: Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.
Study: NCT06241053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal therapy with McConnell taping
Description: Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~Core exercises include curls ups, toa taps, side planks, supine straight leg raising, side lying straight leg raising, prone knee flexion, draw foot circles in supine and side lying, prone cobra, hip and knee extension, weight bearing, hip flexion sitting on ball, wight bearing forward and backward on the ball, stairs up on Swiss ball. Hip training includes Hip abduction, Hip external rotation in standing and sitting. VMO muscle strengthening will includes squats with a ball.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal therapy without McConnell taping
Description: Multimodal therapy without McConnell taping
Study: NCT04840212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender-Sandalwood scented aromatherapy sticker
Description: The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
Study: NCT06212102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin primed ovarian stimulation
Description: HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
Study: NCT05595629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based remote blood pressure monitoring
Description: Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text-message based remote blood pressure monitoring
Description: Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
Study: NCT05863741

Intervention type: DEVICE
Intervention: Implantation of GMK Sphere with conventional instrumentation
Description: Implantation of GMK Sphere with conventional instrumentation (control group)

Intervention type: DEVICE
Intervention: Implantation of GMK Sphere using the NextAR guidance system
Description: Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
Study: NCT05901727

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only.
Study: NCT06387420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: Subjects receive AK117 intravenously.
Study: NCT05279950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)
Description: the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)
Description: the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
Study: NCT06383260

Intervention type: BEHAVIORAL
Intervention: Behavioral diagnostic
Description: Diagnosing the behavioral pattern

Intervention type: BEHAVIORAL
Intervention: Behavioral diagnostic
Description: Diagnosing the behavioral pattern
Study: NCT05695274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise
Description: Experimental group Fibromyalgia patients will be provided with progressive relaxation exercises twice a week. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation.
Study: NCT06387420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subjects receive azacitidine subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Subjects receive azacitidine subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Subjects receive venetoclax orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venetoclax
Description: Subjects receive venetoclax orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo intravenously.
Study: NCT04688229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hummingbird hand training device plus standard of care rehabilitation
Description: The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison (sham) intervention
Description: During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
Study: NCT05513053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
Description: Pharmaceutical form: Solution for injection Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
Description: Pharmaceutical form: Solution for injection Route of administration: intramuscular
Study: NCT05901727

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only.

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only.
Study: NCT05972681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine (1:200,000) injected to the vaginal laceration site.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham normal saline arm
Description: 10 milliliter (ml) of normal saline injected to the vaginal laceration site.
Study: NCT05725785

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FOCUS participants
Description: Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
Study: NCT06403540

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: Using ultrasonography to measure diaphragm thickness